Hematology and Oncology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

James P. Thomas, M.D., Ph.D.

Associate Director, Translational Research

Medical Director, Clinical Trials Office

Section Head, Solid Tumor Oncology

 

 

James Thomas, M.D., Ph.D., joined the faculty at the Medical College of Wisconsin in the Division of Hematology and Oncology in September of 2010. Dr. Thomas received his Ph.D. in Biochemistry and his M.D. from the Medical College of Wisconsin. He completed his residency training in internal medicine at the Medical College of Wisconsin and subsequently completed a fellowship in Medical Oncology at the University of Wisconsin. Dr. Thomas joined the faculty at the University of Wisconsin and was the Disease Leader for Gastrointestinal Cancers. Dr. Thomas served as the Medical Director of the Clinical Trials Office of the Ohio State Comprehensive Cancer Center and was on the NCCN Panel for Colorectal Cancers. He is the Chairman of the American Association of Cancer Institutes Clinical Research Group. Dr. Thomas has published over 70 peer reviewed articles. His research interests are in oncology drug development and in the treatment of gastrointestinal cancers. Dr. Thomas has a long standing research effort in the role of reactive oxygen species in cancer development and treatment.

 Publications

  1. Mulkerin D, LoConte NK, Holen KD, Thomas JP, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase l Study of an oral simulated FOLFOX with high dose capecitabine. Invest. New Drugs 27(5):461-8. October 2009.
  2. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti, MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr., Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. Journal of NCCN 7(8):778-831, September 2009.
  3. Saif SW, H. Oettle, W. L. Vervenne, J.P. Thomas, G. Spitzer, C. Visseren-Grul, N. Enas, D.A. Richards. Randomized double-blind phase ll trial comparing gemcitabine plus LY293111 vs. gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer 15:1-5. July/August 2009 No. 4
  4. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS. Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine:A Single-Institute Study. Oncology. 76(5):333-7, 2009.
  5. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuch CS, Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. Journal of Clinical Oncology. 26(25):4109-15, 2008 Sep 1.
  6. Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 299(21):2515-23, 2008 Jun 4.
  7. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. Journal of Inorganic Biochemistry. 102(4):693-8, 2008 Apr.
  8. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields Anthony LA, Carver G, Mayer RJ, for the Cancer and Leukemia Group B. Irinotecan Fluorouracil and Leucovorin is not superior to Fluorouracil and Leucovorin Alone as Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 J. Clinc Oncol. 25:3456-61, 2007 August 10.
  9. Huie M, Carducci M, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J. Phase l study of piritrexim and gemcitabine in patients with advanced solid tumors. Am J of Clinical Oncology. 28(6):613-617, 2005 Dec.
  10. Thomas JP, Schiller J, Lee F, Perlman S, Friedl A, Winter T, Marnocha R, Arzoomanian R, Alberti D, Binger K, Volkman J, Feierabend C, Tutsch K, Dresen A, Geiger PG, Plunda J, Wilding F. A Phase l Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin. J Clin Onc 21: 223-31, 2003.
webmaster@mcw.edu
© 2014 Medical College of Wisconsin
Page Updated 02/11/2014